Collegium Pharmaceutical's Total Assets for the quarter that ended in Mar. 2024 was $1,114.3 Mil.
Warning Sign:
If a company builds assets at 52.7% a year, faster than its revenue growth rate of 10.1% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Collegium Pharmaceutical's average Total Assets Growth Rate was -15.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 21.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 52.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 108.70% per year.
During the past 11 years, Collegium Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 315.20%. The lowest was 21.00%. And the median was 87.65%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Collegium Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (NAS:COLL) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Collegium Pharmaceutical's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Collegium Pharmaceutical Total Assets Related Terms
Thank you for viewing the detailed overview of Collegium Pharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COLL has been successfully added to your 